Abstract: Certain embodiments in the present invention provide for methods for therapy of lung diseases and other conditions such as infection are provided. In certain embodiments, the methods comprise one or more agents capable of increasing thiol-containing compound transport via a transporter system (i.e., ABC transporters such as MDR-1 or MRP-2) in cells. Other embodiments can include the use of agents to modulate transport of thiol-containing compounds from the cell such as thiocyanate. In certain embodiments, therapeutic methods involve the administration of such agents to a patient afflicted with an inflammatory condition or infection responsive to stimulation of thiol-containing compound transport.

Abstract: Several derivatives of naphthalene, including 1?-acetonaphthone, 2?-acetonaphthone, 1-methoxynaphthalene, and 2-methoxynaphthalene, were discovered to be effective toxicants and repellents of termites, and resulted in significant reduction in termite feeding activity. For example, 2?-acetonaphthone was found to be an effective repellent and feeding deterrent of termites. Termites exposed to concentrations as low as 8 mg/kg sand exhibited a significant reduction in tunneling and feeding activity. Moreover, some of the dead termites had symptoms indicative of a failure to molt. At concentrations ?20 ?g/cm2, 2?-acetonaphthone was a strong repellent. Interestingly, at 160-fold lower concentration (0.125 ?g/cm2), 2?-acetonaphthone stimulated termite feeding activity. As a sand barrier, 2?-acetonaphthone significantly inhibited tunneling and feeding activity in concentrations from 8.33 to 35.0 mg/kg. Molting problems were also identified in termites exposed to 2?-acetonaphthone.

Abstract: The invention provides pharmaceutical compositions and methods of treating immunological disorders. The invention also provides pharmaceutical compositions and methods of inducing eosinophil apoptosis, and methods for treating eosinophil-associated disorders comprising inducing eosinophil apoptosis in an individual in need thereof.

Abstract: The invention provides a multivitamin and mineral nutritional supplement composition comprising at least one polyvalent metal and at least one oxidizable vitamin with substantially improved resistance to reactions that lead to darkening and/or spotting and reactions that may reduce the potency of oxidizable vitamins. The composition is a multivitamin and mineral composition comprising at least one polyvalent metal and at least one oxidizable vitamin wherein the composition is substantially free of mobile bound water. The invention also includes methods for making such a composition and methods of preventing or reducing oxidation, improving the stability of oxidizable vitamins, and stabilizing the disintegration time of a multi-vitamin and mineral nutritional supplement composition.

Abstract: Cancers and/or malignancies can be treated by administration of a cell cycle checkpoint activator, which is preferably ?-lapachone, or a derivative or analog thereof, combined with an oncogenic kinase modulator, preferably imatinib. This combination of the cell cycle checkpoint activator with the oncogenic kinase modulator results in an unexpectedly greater than additive (i.e., synergistic) apoptosis in cancer cells. The invention includes methods of treating cancers by administering the combination of the cell cycle checkpoint activator and the oncogenic kinase modulator, pharmaceutical compositions comprising the combination of drugs used in these methods, as well as pharmaceutical kits.

Abstract: Several derivatives of naphthalene, including 1?-acetonaphthone, 2?-acetpnaphthone, 1-methoxynaphthalene, and 2-methoxynaphthalene, were discovered to be effective toxicants and repellents of termites, and resulted in significant reduction in termite feeding activity. For example, 2?-acetonaphthone was found to be an effective repellent and feeding deterrent of termites. Termites exposed to concentrations as low as 8 mg/kg sand exhibited a significant reduction in tunneling and feeding activity. Moreover, some of the dead termites had symptoms indicative of a failure to molt. At concentrations ?20 ?g/cm2, 2?-acetonaphthone was a strong repellent. Interestingly, at 160-fold lower concentration (0.125 ?g/cm2), 2?-acetonaphthone stimulated termite feeding activity. As a sand barrier, 2?-acetonaphthone significantly inhibited tunneling and feeding activity in concentrations from 8.33 to 35.0 mg/kg. Molting problems were also identified in termites exposed to 2?-acetonaphthone.

Abstract: This invention relates to compositions comprising co-crystals of (?)-gossypol with a C1-8 carboxylic acid or C1-8 sulfonic acid which are useful as inhibitors of Bcl-2 family proteins. The invention also relates to the use of co-crystals of (?)-gossypol with a C1-8 carboxylic acid or C1-8 sulfonic acid for inducing apoptosis in cells and for sensitizing cells to the induction of apoptotic cell death.

Abstract: The present invention relates to an orally administered compound, for preventing neonatal hemorrhages, in a tardy form, caused by a K-vitamin deficiency, comprising K1 vitamin, in an oil solution, to be administered in daily microdoses.

Abstract: Compositions, methods and the like comprising fucans such as fucoidan to treat surgical adhesions, arthritis, and psoriasis.

Abstract: A pharmaceutical or cosmetic carrier or composition for topical application characterized by rheological properties which render the carrier or composition semi-solid at rest and a liquid upon application of shear forces thereto. The composition or carrier are prepared by mixing 1–25 percent of a solidifying agent and 75–99 percent of a hydrophobic solvent, by weight, wherein at least one of them has therapeutic or cosmetic benefits, in the presence or absence of a biologically active substance.

Abstract: We have now discovered that certain 9,10-anthraquinone derivatives we developed possess potent activity against O. perornata while possessing a sufficiently high level of solubility in water to make their activity against O. perornata viable. These compounds possess a high level of activity against O. perornata yet are relatively non-toxic to green algae and fishes. The compounds also possess a relatively short half-life. The compounds represent a new means to providing compounds possessing a high degree of selective activity against blue-green algae while being physiologically tolerated by catfish and green algae. The compounds provide a means for controlling blue-green algae in managed bodies of water that are destined for public use or consumption.

Abstract: Substituted naphthalenediones in accord with structural diagram (I): compositions thereof and methods for the use thereof, for the treatment of T cell mediated conditions such as autoimmune diseases and organ graft rejection.

Abstract: Pharmaceutical formulation, its method of preparation, and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethyl sulfoxide; a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone. The pharmaceutical formulation is used to treat horses infected with Sarcocystis protozoal infections.

Abstract: An antimicrobial compound, composition containing such compound, and method of use of the same for reducing the presence of microorganism on a substrate or in a fluid environment comprising an antimicrobial effective carrier and one or more essential antimicrobial compounds including non-halogenated naphthol compounds.

Abstract: Naphthoquinone derivatives of Formula (1): wherein R, represents an OH group, methyl ether, ethyl ether or a similar ether, R1 represents a methyl, ethyl or similar aliphatic hydrocarbon derivative: R2 and R3 each independently represent hydrogen or a group selected from: (A), (B), or (C) wherein R5 represents an PH group, methyl ether, ethyl ether or a similar ether and R6 represents a methyl, ethyl or similar aliphatic hydrocarbon derivative: R4 represents hydrogen or a group selected from: (D), (E) or (F) wherein R7 represents an OH group, methyl ether, ethyl ether or a similar ether and R8 represents a methyl, ethyl or similar aliphatic hydrocarbon derivative: or pharmaceutically acceptable salts thereof, are useful for the treatment and/or control of a tuberculosis in a patient caused by Mycobacterium tuberculosis.

Abstract: The present invention relates to a pharmaceutical composition comprising at least one active compound having cytostatic activity, at least one biological electron acceptor and customary pharmaceutical additives, and to its use for the treatment of tumor diseases, in particular for the treatment of cancer.

Abstract: Aldose redcutase inhibitor and pharmaceutically acceptable derivatives thereof of the formula I below derived from cultures of Aspergillus niger CFR 1046 and useful as a rat lens aldose reductase inhibitor

Abstract: The use of a pharmaceutical formulation in treating coronary arteriosclerosis and a two-component pharmaceutical formulation. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimithyl sulfoxide; a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone.

Abstract: A combination anticoagulation medicament including vitamin K with warfarin in an oral form is described. Between 50 and 5000 micrograms of vitamin K are combined in a single oral medication with 0.5 to 15 milligrams of warfarin for administration. The combination of vitamin K with warfarin in a single orally dosed form is a novel approach to improving the effectiveness of anticoagulation. The combination allows for broader application of warfarin in medical anticoagulation and reduces the variability of anticoagulation due to the influences of diet, additional medications, nutritional status, changes in physical condition, and potentially other factors. Use of the combination therapy improves the safety of warfarin as an appropriate anticoagulant for many medical conditions.

Abstract: The present invention provides methods and kits for treating osteoarthritis using an estrogen agonist/antagonist.

Abstract: The present invention relates to the use of one or more of apigenin, luteolin and morin and functional analogues thereof for the manufacture of a preparation for the treatment and/or prevention of a disorder related to altered bone metabolism, in particular osteoporosis, osteopenia, Paget's disease, osteolytic metastasis in cancer patients, osteodistrophy in liver disease or the altered bone metabolism caused by renal failure or haemodialysis, bone fracture, bone surgery, pregnancy, anorexia nervosa, and in immobile, malnourished and weight losing persons.

Abstract: A composition and a method for administering an improved supplement to prevent bone density loss. The composition combines a calcium compound with inulin, and optionally magnesium, Vitamin D3, Vitamin K, Vitamin C, and may combine a soy isoflavone, all in a dietary acceptable form in a beverage, a beverage preparation, a paste, a bar, or a cookie.

Abstract: We have surprisingly discovered that the administration of a G1 and/or S phase drug such as &bgr;-lapachone in combination with a G2/M drug such as a taxane derivative such as paclitaxel resulted in an unexpected greater than additive (i.e., synergistic) reduction in the number of tumors (and tumor volume) as compared with the administration of these agents alone. In addition, no signs of toxicity or weight loss were observed. The present invention relates to a method for treating a mammalian tumor using combinations such as a taxane derivative, preferably paclitaxel, and a &bgr;-lapachone, or a derivative or analog thereof.

Abstract: A composition, useful in the prevention of osteoporosis, wherein said composition comprises (a) least one isoflavone and/or isoflavone glycoside, preferably genistein and/or genistin; (b) at least one polyunsaturated fatty acid; (c) optionally vitamin D, and /or one or more derivatives thereof and /or vitamin K and/or one or more derivatives thereof; and (d) optionally adjuvants and excipients in quantities as required, preferably within the range of 0.1 to 20% by weight, based on the total weight of the composition. Dietary compositions and galenical forms made therefrom and the use of said compositions for preventing osteoporosis and stimulating osteogenesis in mammals.

Abstract: Beta-lapachone, which is poorly soluble in most pharmaceutically acceptable solvents, has demonstrated significant antineoplastic activity against human cancer lines. The present invention overcomes this significant limitation by teaching novel pharmaceutical compositions comprising a therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, and a pharmaceutically acceptable solubilizing carrier molecule, which may be at water-solubilizing carrier molecule such as hydroxypropyl-&bgr;-cyclodextrin, or an oil-based solubilizing carrier molecule, for enhancing the solubility of Beta-lapachone in aqueous solution. The therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, may be complexed with the pharmaceutically acceptable solubilizing carrier molecule in aqueous solution. The novel pharmaceutical compositions may be administered with a second anticancer agent or in combination with radiation therapy.

Abstract: A method of reducing or inhibiting mucositis in a patient, which includes administering an inflammatory cytokine inhibitor or a mast cell inhibitor, or a combination thereof, is disclosed.

Abstract: Pharmaceutical compositions and methods for treating androgen related disorders. The pharmaceutical compositions may include a 5&agr;-reductase inhibitor, such as natural and synthetic flavanoids, catechols, curcumin-related substances, quinones, catechins, particularly epigallocatechin derivatives, fatty acids, and the salts, esters, analogues, pro-drugs, isomers, racemic mixtures, or derivatives of any of the foregoing. The use of testosterone (or DHT) combinations with the aforementioned 5&agr;-reductase inhibitor compounds is also contemplated.

Abstract: An antimicrobial compound, composition containing such compound, and method of use of the same for reducing the presence of microorganism on a substrate or in a fluid environment comprising an antimicrobial effective carrier and one or more essential antimicrobial compounds including non-halogenated naphthol compounds.

Abstract: The present invention provides a novel compound having an excellent acetylcholinesterase inhibitory effect. That is, it provides a 4-substituted piperidine compound fluoride represented by the following formula, a pharmaceutically acceptable salt thereof or hydrates thereof (provided that 1-benzyl-4-[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methylpiperidine, a pharmaceutically acceptable salt thereof and hydrates thereof are excluded). wherein R1 and R2 represent substituents.

Abstract: The key to the unique formulation is a combination of specific vitamins, minerals, herbs and nutrients. These essential components in the amounts provided uniquely contribute to improved blood sugar levels and insulin delivery to the cells. The formulation contains essential amounts of Calcium, magnesium Vitamin D, Vitamin K-1, Folic Acid and Soy Isoflavones, as well as other ingredients and healthy filler components.

Abstract: Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs, particularly steroids, are provided. The pharmaceutical compositions include a therapeutically effective amount of a hydrophobic drug, preferably a steroid; a solubilizer, preferably a vitamin E substance; and a surfactant. The synergistic effect between the hydrophobic drug and the vitamin E substance results in a pharmaceutical formulation with improved dispersion of both the active agent and the solubilizer. As a result of the improved dispersion, the pharamaceutical composition has improved bioavailability upon administration. Methods of improving the bioavailability of hydrophobic drugs administered to a patient are also provided.

Abstract: Citreamicins possess useful antitumor activity. Typically they are of formula, wherein R1 is selected from the group consisting of COCH2CH(CH3)2, COCH3 or H when R2 is CH3, or wherein R1 is COCH2CH(CH3)2, and R2 is H.

Abstract: Purified soy phosphatidylserine is used to make cochleates. The cochleates contain at least about 75% soy phosphatidylserine and optionally a bioactive load. A preferred cochleate contains the antifungal agent amphotericin B.

Abstract: The invention relates to a process for the production of microfluidized particles of atovaquone having improved bioavailability.

Abstract: Methods for preparing dry powders having hydrophobic and hydrophilic components comprise combining solutions of the components and spray drying them simultaneously in a spray dryer. The hydrophilic and hydrophobic component are separately dissolved in separate solvents and directed simultaneously through a nozzle, usually a coaxial nozzle, into the spray dryer. The method provides dry powders having relatively uniform characteristics.

Abstract: The invention relates to the use of one or more compounds from the bioquinone group for producing cosmetic or dermatological preparations for treating the scalp and the hair, in order to prolong the anagen phase and/or to treat and prevent seborrhoeic outbreaks, optionally with the additional use of one or more compounds from the group formed by carnitine, arginine, succinic acid, folic acid, conjugated fatty acids and their respective derivatives, in addition to antioxidants.

Abstract: The invention relates to method for the enhancement of the activity and/or systemicity of fungicidal compositions containing at least one benzoylbenzene of formula I wherein R1 through R7, m and n are as defined in claim 1, with the aid of one or more adjuvants selected from the group consisting of (a) alkylpolyglycosides, alkenyl succinic acid derivatives, dialkyl sulfosuccinates, polyvinylpyrrolidones, perfluoroalkyl acids derivatives, perfluoro(C3-20)alkyl esters of carboxylic acids, and mixtures thereof; (b) alkoxylated alcohols, amines or acids; (c) water-immiscible polar aprotic solvents; and to the use of such a composition as a fungicide.

Abstract: This invention also provides a method to inhibit neovascularization in tissue by delivering to the cell or tissue an effective amount of gossypol, or a pharmaceutically acceptable salt, derivative or prodrug thereof. Also provided herein is a method for treating a disease associated with hyproliferation of endothelial cells and/or neovascularization by administering to a subject an effective amount of gossypol, or a pharmaceutically acceptable salt, derivative or prodrug thereof. Kits to treat patients are provided as well.

Abstract: The present invention relates to the use of a compound of formula (I): 1

Abstract: A therapeutic formulation in the form of a beadlet, suitable for oral administration and adapted to provide immediate and sustained release of therapeutic material. Each beadlet comprises an extruded-spheronized inner core containing at least one medicament e.g. a slow release vitamin, an outer layer containing at least one medicament e.g. a fast release vitamin and a controlled release coating between the inner core and the outer layer which coating controls the release of the inner core medicament.

Abstract: Topoisomerase inhibitors are useful for the treatment of inflammatory disorders including arthritis, restenosis, surgical adhesions and other diseases. Controlled release polymeric formulations to topoisomerase inhibitors are particularly suitable for this use.

Abstract: A use of tetralin derivatives as biocidal and antifouling agents for preventing and slowing the growth of algae, molds and microorganisms. In particular, the vitamin derivatives are constituted by salts of menadione bisulfite with the heterocyclic bases triazine and piperazine.

Abstract: In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of a pharmaceutically active agent, wherein the agent is associated with a polymeric biocompatible material.

Abstract: The present invention relates to stable emulsions and dry powders of mixtures of fat-soluble vitamins, and to processes for their preparation and to their use.

Abstract: The invention relates to compositions for promoting and inhibiting osteogenesis and to methods for treating bone abnormalities resulting from injury, toxicity or disease and for ex vivo bone tissue engineering.

Abstract: Substituted naphthalenediones in accord with structural diagram (I): compositions thereof and methods for the use thereof, for the treatment of T cell mediated conditions such as autoimmune diseases and organ graft rejection. In compounds of the invention, wherein: Q1 at each occurrence is independently selected from hydrogen, hydroxy, halogen, C(O)O(C1-C3) alkyl and C(O)phenyl, and Q2 is selected from hydrogen, halogen, O—(C1-C3)alkyl, O—(C1-C3)alkenyl, phenyl, indolyl and naphthyl, where phenyl may be mono- or di-substituted with NO2 or halogen, and indolyl may be substituted with (C1-C3)alkyl or phenyl.

Abstract: Compounds that inhibit 5-alpha-reductase are provided. The compounds are used to treat prostate cancer, breast cancer, obesity, skin disorders and baldness.

Abstract: Dietary supplement compositions designed to be responsive to specific blood types, and thus most beneficial for people with specific antigenic blood types.

Abstract: The present invention provides therapeutically effective amounts of 6MNA prodrugs. The pharmaceutical composition comprises wherein R is H or COR′, wherein R′ is selected from the group consisting of C1 to C6 alkyl, (CH2)m O(CH2)n, (CH2)m(OC2H4)p O(CH2)n, (CH2)m(OC2H4)p, (OCH2H4)p ONO2 and (OCH2H4)p O(CH2)n wherein m is an integer from 2 to 4, and n and p are integers from 1 to 4. Alternatively, R is a therapeutic moiety.

Abstract: The present invention relates to a therapeutic agent for ischemia which inhibits apoptosis under ischemic condition. The therapeutic agent of present invention comprises antibacterial agents of quinolones, quinones, aminoglycosides or chlorampheni-col as an active ingredient. Since the invented therapeutic agent improved the viability of cells under hypoxic and hypoglycemic condition, it can be clinically for ischemic diseases such as applied as a potentiad drug for ischemia-associated infarction and cerebral infarction.